Based on its current operating plans, Xilio anticipates that its cash and cash equivalents as of March 31, 2025 will be sufficient to enable it to fund its operating expenses and capital expenditure requirements into the first quarter of 2026.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XLO:
- AbbVie Stock (ABBV) Up 8% on the Week as Company Soars Past Q1 Expectations
- Xilio Therapeutics: Strategic Pivot and Promising Pipeline Drive Buy Rating
- Promising Clinical Developments and Strong Financial Outlook Justify Buy Rating for Xilio Therapeutics
- Xilio Therapeutics Reports 2024 Financial Results and Pipeline Progress
- Xilio Therapeutics files $250M mixed securities shelf